{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:24:33Z","timestamp":1768796673518,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canrad.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:52:31Z","timestamp":1724475151000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tol\u00e9rance \u00e0 court et moyen terme d\u2019une radioth\u00e9rapie prostatique hypofractionn\u00e9e selon la technique du boost int\u00e9gr\u00e9"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1969-2286","authenticated-orcid":false,"given":"Laur\u00e8ne","family":"Larrivi\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Thomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Bakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Calais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.04.004_bib0225","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990\u00a0et 2018\u00a0: \u00e9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim","author":"Defossez","year":"2019"},{"key":"10.1016\/j.canrad.2024.04.004_bib0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D.\u00a0Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0235","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0240","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jamaoncol.2015.2419","article-title":"Dose-escalated radiotherapy for prostate cancer: is the sky the limit?","volume":"1","author":"Gray","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01\u00a0randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0250","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70\u00a0Gy versus 80\u00a0Gy in localized prostate cancer: 5-year results of G\u00e9tug 06\u00a0randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0255","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0260","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0265","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969\u00a0patients in seven international institutional datasets: \u03b1\/\u03b2\u00a0=\u00a01.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0270","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/0284186X.2018.1433874","article-title":"Clinical estimation of \u03b1\/\u03b2 values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy","volume":"57","author":"Datta","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0275","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0280","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose-response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0285","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0290","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3\u00a0trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0295","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3\u00a0CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0300","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0305","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0310","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.purol.2022.07.148","article-title":"Cancer Committee Guidelines\u00a0\u2013\u00a0update 2022\u20132024: prostate cancer\u00a0\u2013\u00a0diagnosis and management of localised disease","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0315","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0320","first-page":"S94","article-title":"Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: dose-effect relations in the POP-RT randomized phase III trial","volume":"35","author":"Maitre","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.07.018","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: long term results from a prospective clinical trial","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0330","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COC.0000000000000133","article-title":"Late toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated IMRT and long-term androgen suppression treatment","volume":"40","author":"Pervez","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0335","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2022.07.2323","article-title":"Conventional vs. hypofractionated, radiotherapy for high-risk prostate cancer: 7-year outcomes of the randomized, non-inferiority, phase 3\u00a0PCS5\u00a0trial","volume":"114","author":"Niazi","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0340","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.3390\/cancers13194970","article-title":"Ten year results of extensive nodal radiotherapy and moderately hypofractionated simultaneous integrated boost in unfavorable intermediate-, high-, and very high- risk prostate cancer","volume":"13","author":"Di Muzio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2024.04.004_bib0345","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.adro.2019.11.007","article-title":"Ten-year results from a phase II study on image guided, intensity modulated radiation therapy with simultaneous integrated boost in high-risk prostate cancer","volume":"5","author":"Ekanger","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0350","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","article-title":"The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"188","author":"Hodapp","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0360","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2010.11.003","article-title":"Hypofractionated concomitant intensity-modulated radiotherapy boost for high- risk prostate cancer: late toxicity","volume":"82","author":"Quon","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0365","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3109\/0284186X.2012.748987","article-title":"Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer","volume":"52","author":"McDonald","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0370","first-page":"100702","article-title":"Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer","volume":"44","author":"Masson","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0375","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2023.05.014","article-title":"Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the Prostate Cancer Study-5, a Groupe de radio-oncologie g\u00e9nito-urinaire de Qu\u00e9bec-led phase 3\u00a0trial","volume":"118","author":"Niazi","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0385","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2021.02.011","article-title":"Clinical outcomes of the CHIRP trial: a phase II prospective randomized trial of conventionally fractionated versus moderately hypofractionated prostate and pelvic nodal radiation therapy in patients with high-risk prostate cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0390","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12253-019-00623-2","article-title":"Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. A single institution, prospective study","volume":"26","author":"Jorgo","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.canrad.2024.04.004_bib0395","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3\u00a0trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0400","first-page":"22","article-title":"PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0405","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose\u2013response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68\u00a0Gy of radiotherapy with 78\u00a0Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0410","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M.D.\u00a0Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0415","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0420","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01\u00a0randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0425","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.canrad.2020.11.004","article-title":"Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa)","volume":"25","author":"Peyraga","year":"2021","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2024.04.004_bib0430","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An Updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.04.004_bib0435","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.04.004_bib0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2019.09.039","article-title":"A multicenter phase 2\u00a0study of hypofractionated stereostatic boost in intermediate risk prostate carcinoma: a 5-year analysis of the CKNO-PRO trial","volume":"106","author":"Pasquier","year":"2020","journal-title":"Int J Radiat Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:16:50Z","timestamp":1733055410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1278321824001008"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.04.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance \u00e0 court et moyen terme d\u2019une radioth\u00e9rapie prostatique hypofractionn\u00e9e selon la technique du boost int\u00e9gr\u00e9","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}